878745-39-2

Upstream product

• 660838-05-1 t-butyl 3-amino-4-methylphenylcarbamate 
• 16064-09-8 6-chloro-3-methylquinazolin-4(3H)-one 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 635-21-2 5-chloroanthranilic acid 
• 630410-29-6 (4-methyl-3-nitro-phenyl)-carbamic acid tert-butyl ester 
• 119-32-4 4-Methyl-3-nitroanilin 
• 24424-99-5 di-tert-butyl dicarbonate 
• 57573-59-8 6-bromo-3-N-methylquinazoline-4(3H)-one 

Downstream Products

• 1422175-99-2 C₂₇H₁₉F₄N₅O₃ 
• 1422176-00-8 C₂₇H₁₉F₄N₅O₃ 
• 1422175-70-9 C₂₇H₂₃FN₆O₄S 
• 878745-42-7 6-(5-amino-2-methylphenylamino)-3-methylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS

The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors

B-Raf protein kinase, which is a key signaling molecule in the RAS-RAF-MEK-ERK signaling pathway, plays an important role in many cancers. The B-Raf V600E mutation represents the most frequent oncogenic kinase mutation known and is responsible for increas

SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.